Home
News
Videos
Podcasts
Menu
Акционерное общество "ТВ БРИКС"
tvbrics@tvbrics.com
Рубцов переулок, д.13, Москва, 105082, RU
+74996425304
Currencies:
RUB/USD 0,012
0,0001
BRL/USD 0,1937
0,0009
INR/USD 0,0104
0,0000
CNY/USD 0,1487
0,0000
ZAR/USD 0,0624
0,0000
IDR/USD 0,0001
0,0000
SPACE FOR MEDIA DIPLOMACY
21:15 «BRICSterview»
21:15 «BRICSterview»
Now 16+
21:15

«BRICSterview»

It is indicated Moscow time in the programme. Please take into account the time difference with your time zone.
21:45 «Russian Lessons with Tanya Semke»
Next
21:45

«Russian Lessons with Tanya Semke»

16+
22:00

Documentary film «Worthy of Applause: New Roles for BRICS+ Actors»

16+
22:30

«City of stories»

16+
Menu
Broadcast «BRICSterview»
RUB/USD
0,012
0,0001
BRL/USD
0,1937
0,0009
INR/USD
0,0104
0,0000
CNY/USD
0,1487
0,0000
ZAR/USD
0,0624
0,0000
IDR/USD
0,0001
0,0000
TV BRICS Apps
Russia advances development of cancer vaccines with early clinical use underway

Authorities highlight breakthrough potential as personalised mRNA therapies enter initial application stage


Russia has announced significant progress in the development of vaccines targeting cancer and autoimmune diseases, with early clinical use already underway and broader applications under consideration, reports Prensa Latina, a partner of TV BRICS.

President of the Russian Academy of Sciences Gennady Krasnikov stated that national researchers are actively working on innovative vaccine technologies, particularly in oncology and immunology. He emphasised that the scientific potential in this field is considerable, although further progress will depend largely on sustained funding.

Earlier, the Ministry of Health of Russia confirmed the first use of a personalised mRNA vaccine for the treatment of melanoma in a patient. The case marks an important step in the practical application of advanced therapies tailored to individual patients, experts believe.

According to the Chief oncologist of the Ministry of Health and academician Andrey Kaprin, the use of mRNA-based treatments could expand beyond melanoma if current results prove successful. Researchers are closely monitoring outcomes to assess the broader clinical potential of this approach.

Government officials have also indicated that several cancer vaccines are in the process of registration, with plans to integrate them into the national compulsory health insurance system if trials confirm their safety and efficacy.

Experts underline that advances in vaccine technology may significantly strengthen the country’s position in global biomedical research, particularly in the rapidly evolving field of personalised medicine.